CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma to participate in BIO-Europe 2026

4 Nov 2026, 10:00

Lund, Sweden, November 4. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a panel titled “Immunology under the microscope: New frontiers” at BIO-Europe 2026, on Tuesday 10 November, at 14:00 CET, at the Koelnmesse, in Cologne, Germany.

If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at [email protected].

Event: Panel at BIO-Europe 2026

Title: Immunology under the microscope: New frontiers

Date, Time and Place: Tuesday 10 November, 14:00 CET, Koelnmesse, Cologne, Germany

Moderated by: Sam Possemiers, CEO, MRM Health

Panellists:

  • Renée Aguiar-Lucander, CEO, Hansa Biopharma
  • Samuel Black, Senior Director Global Business Development, Merck KGaA
  • Giulia Vestri, Partner, Claris Ventures

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
[email protected]

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at  www.hansabiopharma.com  and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

Files